Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: A description of 26 participants

Original research
par
MacDonald, T. et al

Date de publication

2022

Géographie

Australia

Langue de la ressource

English

Texte disponible en version intégrale

Non

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

Discontinuation from benzodiazepines can be problematic for patients and may result in a withdrawal syndrome, which can be protracted and last months to years.

Constatations/points à retenir

Self-reported rates of abstinence from benzodiazepines at three months was between 46.2% and 61.5%. Flumazenil may yield greater success than benzodiazepine tapering from high dose (>30 mg diazepam equivalent) benzodiazepine use.

La conception ou méthodologie de recherche

26 participants received low-dose subcutaneous flumazenil infusions (4 mg/24 h for approximately eight days) as part of a randomised control crossover trial.

Mots clés

Clinical guidance
Overdose
Outcomes